mdtravel launches dérive, an online booking solution to simplify corporate travel management for the pharmaceutical and healthcare industries
Berkshire, January 25, 2018/ - - There are several corporate booking tools on the market, but none like dérive: the online corporate travel management solution that meets the specific needs of pharmaceutical and biotech executives, physicians and patients.
Launched this week by mdtravel (part of mdgroup), a specialist travel management company for the pharmaceutical and healthcare industries, dérive is a total business travel management solution, offering healthcare travellers greater convenience, while reducing costs and compliance complications for companies.
dérive centralises and streamlines the booking process, offering travellers 24/7 access to flights, trains, transfers and accommodation at discounted rates. Fees are based on a per booking basis, so clients only pay for the services they require and that comply with company travel policies.
dérive: enhancing Pharma’s corporate travel experience
Commenting on the launch, Eloise Moffett, Business Development Manager, mdtravel states:
“dérive delivers a better corporate travel experience for healthcare and pharma executives and their employers. The name dérive reflects the traveller-centric nature of the booking solution and our traffic light system ensures compliance with corporate travel policies.”
Tarquin Scadding-Hunt, mdgroup CEO says: “Our goal is to simplify our clients’ travel management at every stage. With dérive, we’re helping clients manage travel-related bookings and costs, while providing peace of mind with live employee tracking and
24-hour support services".
Email eloise.moffet[email protected] to find out what dérive can do for your business.
mdgroup is the parent company of mdevents, patientprimary and mdtravel. We’re committed to getting life-saving products to patients faster, by providing services and software solutions that help pharmaceutical and biotech companies engage employees, physicians and patients in clinical trials and drug development.